BACKGROUND: Major depressive disorder (MDD) occurs in a subset of patients receiving interferon-alpha treatment, although many are resilient to this side effect. Genetic differences in the serotonin reuptake transporter promoter (5-HTTLPR) may interact with the inflammatory system and influence depression risk. METHODS: A cohort of 71 nondepressed hepatitis C patients about to receive interferon-alpha was prospectively followed, employing a diagnostic structured clinical interview (Structured Clinical Interview for DSM-IV Axis I Disorders [SCID-I]) and self-report questionnaires. Patients were genotyped for the 5-HTTLPR (L(G), L(A), and S) and the variable number of tandem repeats (VNTR) polymorphism in the second intron. Kaplan-Meier analyses were used to compare major depression incidence. Genotype effects on sleep quality (Pittsburgh Sleep Quality Index) and Beck Depression Inventory (BDI) were assessed using mixed-effect repeated-measure analyses. RESULTS: The L(A) allele was associated with a decreased rate of developing MDD (Mantel-Cox log rank test p < .05) with the L(A)/L(A) genotype being the most resilient. This genotype was also associated with better sleep quality [F(61.2,2) = 3.3, p < .05]. The ability of baseline sleep quality to predict depression incidence disappeared when also including genotype in the model. Conversely, the relationship of neuroticism with depression incidence (B = .07, SE = .02, p < .005) was not mitigated when including genotype. CONCLUSIONS: Using a prospective design, 5-HTTLPR is associated with MDD incidence during interferon-alpha treatment. Preliminary evidence that this effect could be mediated by effects on sleep quality was observed. These findings provide support for a possible interaction between inflammatory cytokine (interferon-alpha) exposure and 5-HTTLPR variability in MDD.
BACKGROUND: Major depressive disorder (MDD) occurs in a subset of patients receiving interferon-alpha treatment, although many are resilient to this side effect. Genetic differences in the serotonin reuptake transporter promoter (5-HTTLPR) may interact with the inflammatory system and influence depression risk. METHODS: A cohort of 71 nondepressed hepatitis Cpatients about to receive interferon-alpha was prospectively followed, employing a diagnostic structured clinical interview (Structured Clinical Interview for DSM-IV Axis I Disorders [SCID-I]) and self-report questionnaires. Patients were genotyped for the 5-HTTLPR (L(G), L(A), and S) and the variable number of tandem repeats (VNTR) polymorphism in the second intron. Kaplan-Meier analyses were used to compare major depression incidence. Genotype effects on sleep quality (Pittsburgh Sleep Quality Index) and Beck Depression Inventory (BDI) were assessed using mixed-effect repeated-measure analyses. RESULTS: The L(A) allele was associated with a decreased rate of developing MDD (Mantel-Cox log rank test p < .05) with the L(A)/L(A) genotype being the most resilient. This genotype was also associated with better sleep quality [F(61.2,2) = 3.3, p < .05]. The ability of baseline sleep quality to predict depression incidence disappeared when also including genotype in the model. Conversely, the relationship of neuroticism with depression incidence (B = .07, SE = .02, p < .005) was not mitigated when including genotype. CONCLUSIONS: Using a prospective design, 5-HTTLPR is associated with MDD incidence during interferon-alpha treatment. Preliminary evidence that this effect could be mediated by effects on sleep quality was observed. These findings provide support for a possible interaction between inflammatory cytokine (interferon-alpha) exposure and 5-HTTLPR variability in MDD.
Authors: Kathleen R Merikangas; Aravinda Chakravarti; Steven O Moldin; Houmam Araj; John C Blangero; Margit Burmeister; John Crabbe; J Raymond Depaulo; Edward Foulks; Nelson B Freimer; Doreen S Koretz; William Lichtenstein; Emmanuel Mignot; Allan L Reiss; Neil J Risch; Joseph S Takahashi Journal: Biol Psychiatry Date: 2002-09-15 Impact factor: 13.382
Authors: Lucile Capuron; Jane F Gumnick; Dominique L Musselman; David H Lawson; Andrea Reemsnyder; Charles B Nemeroff; Andrew H Miller Journal: Neuropsychopharmacology Date: 2002-05 Impact factor: 7.853
Authors: Lucile Capuron; Gabriele Neurauter; Dominique L Musselman; David H Lawson; Charles B Nemeroff; Dietmar Fuchs; Andrew H Miller Journal: Biol Psychiatry Date: 2003-11-01 Impact factor: 13.382
Authors: Gary K Geiss; Victoria S Carter; Yupeng He; Bartlomiej K Kwieciszewski; Ted Holzman; Marcus J Korth; Catherine A Lazaro; Nelson Fausto; Roger E Bumgarner; Michael G Katze Journal: J Virol Date: 2003-06 Impact factor: 5.103
Authors: Michael R Irwin; Steve Cole; Richard Olmstead; Elizabeth C Breen; Joshua Jin Cho; Mona Moieni; Naomi I Eisenberger Journal: Neuropsychopharmacology Date: 2018-11-03 Impact factor: 7.853
Authors: Jennifer C Felger; Jiyoung Mun; Heather L Kimmel; Jonathon A Nye; Daniel F Drake; Carla R Hernandez; Amanda A Freeman; David B Rye; Mark M Goodman; Leonard L Howell; Andrew H Miller Journal: Neuropsychopharmacology Date: 2013-05-09 Impact factor: 7.853